Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 1

Макролиды: современная позиция в пульмонологической практике
Н.Б. Лазарева, Е.В. Реброва, А.Ю. Рязанова, Д.А. Бондаренко, Д.Д. Савинцева

References

1. Lewis K. Platforms for antibiotic discovery. Nature Reviews. Drug Discovery 2013 May;12(5):371-87.
2. Golkar T, Zielinski M, Berghuis AM. Look and outlook on enzyme-mediated macrolide resistance. Frontiers in Microbiology 2018 Aug;9:1942.
3. Gomes C, Martínez-Puchol S, Palma N, Horna G, Ruiz-Roldán L, Pons MJ, Ruiz J. Macrolide resistance mechanisms in Enterobacteriaceae: focus on azithromycin. Critical Reviews in Microbiology 2017 Feb;43(1):1-30.
4. Instruction for medical use of oletetrin. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=611e2a28-61ed-4414-bc51-102645c5afbf&t= Accessed 2019 Aug 13 (In Russian).
5. Donald BJ, Surani S, Deol HS, Mbadugha UJ, Udeani G. Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy. Drug Design, Development and Therapy 2017 Dec;11:3559-66.
6. Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Canadian Journal of Infectious Diseases & Medical Microbiology 2015 Nov-Dec;26(6):305-12.
7. Svetlov MS, Vázquez-Laslop N, Mankin AS. Kinetics of drug-ribosome interactions defines the cidality of macrolide antibiotics. Proceedings of the National Academy of Sciences of the USA 2017 Dec;114(52):13673-8.
8. Van Bambeke F. Renaissance of antibiotics against difficult infections: focus on oritavancin and new ketolides and quinolones. Annals of Medicine 2014 Nov;46(7):512-29.
9. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clinical Infectious Diseases 2012 Aug;55(Suppl 2):S127-31.
10. Su W, Kumar V, Ding Y, Ero R, Serra A, Lee BST, Wong ASW, Shi J, Sze SK, Yang L, Gao YG. Ribosome protection by antibiotic resistance ATP-binding cassette protein. Proceedings of the National Academy of Sciences of the USA 2018 May;115(20):5157-62.
11. Sharkey LK, Edwards TA, O’Neill AJ. ABC-F proteins mediate antibiotic resistance through ribosomal protection. mBio 2016 Mar;7(2):e01975.
12. Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001–2004. Journal of Infection 2007 Aug;55(2):111-8.
13. Wolter N, von Gottberg A, du Plessis M, de Gouveia L, Klugman KP; Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. Molecular basis and clonal nature of increasing pneumococcal macrolide resistance in South Africa, 2000–2005. International Journal of Antimicrobial Agents 2008 Jul;32(1):62-7.
14. Song JH, Chang HH, Suh JY, Ko KS, Jung SI, Oh WS, Peck KR, Lee NY, Yang Y, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumararasinghe G, Jamal F, Kamarulazaman A, Parasakthi N, Van PH, So T, Ng TK; ANSORP Study Group. Macrolide resistance and genotypic characterization of Streptococcus pneumoniae in Asian countries: a study of the Asian Network for Surveillance of Resistant Pathogens (ANSORP). The Journal of Antimicrobial Chemotherapy 2004 Mar;53(3):457-63.
15. Fyfe C, Grossman TH, Kerstein K, Sutcliffe J. Resistance to macrolide antibiotics in public health pathogens. Cold Spring Harbor Perspectives in Medicine 2016 Oct;6(10). pii: a025395.
16. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, Ki HK, Oh WS, Suh JY, Peck KR, Lee NY, Yang Y, Lu Q, Chongthaleong A, Chiu CH, Lalitha MK, Perera J, Yee TT, Kumarasinghe G, Jamal F, Kamarulzaman A, Parasakthi N, Van PH, Carlos C, So T, Ng TK, Shibl A. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrobial Agents and Chemotherapy 2004 Jun;48(6):2101-7.
17. Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. International Journal of Infectious Diseases 2013 Jun;17(6):e364-73.
18. Nathan JJ, Taib NM, Desa MNM, Masri SN, Yasin RM, Jamal F, Sagineedu SR, Karunanidhi A. Prevalence of macrolide resistance and in vitro activities of six antimicrobial agents against clinical isolates of Streptococcus pneumoniae from a multi-center surveillance in Malaysia. The Medical Journal of Malaysia 2013;68(2):119-24.
19. Pereyre S, Goret J, Bébéar C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Frontiers in Microbiology 2016 Jun;7:974.
20. Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics. Future Microbiology 2011 Apr;6(4):423-31.
21. Zaytsev SV, Zastrozhina AK, Murtazayeva OA. Mycoplasma infection in children (review of literature). Russian Medical Journal 2017;25(5):327-34 (In Russian).
22. Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K, Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. The New England Journal of Medicine 1997 Aug;337(7):441-6.
23. Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM, Glasziou PP, Hoffmann TC, Clark J, Del Mar CB. Adverse events in people taking macrolide antibiotics versus placebo for any indication. The Cochrane Database of Systematic Reviews 2019 Jan;(1):CD011825.
24. Abu-Gharbieh E, Vasina V, Poluzzi E, De Ponti F. Antibacterial macrolides: a drug class with a complex pharmacological profile. Pharmacological Research 2004 Sep;50(3):211-22.
25. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. International Journal of Antimicrobial Agents 2016 Jul;48(1):1-10.
26. Moseley RH. Macrolide antibiotics. Hepatotoxicity of antimicrobials and antifungal agents. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier; 2013: 466-7.
27. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. Journal of Pharmacology and Experimental Therapeutics 2002 Jul;302(1):320-7.
28. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, Iga T. Comparative pharmacodynamic analysis of Q–T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrobial Agents and Chemotherapy 2000 Oct;44(10):2630-7.
29. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clinical Infectious Diseases 2002 Jul;35(2):197-200.
30. Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Die Pharmazie 2010 Sep;65(9):631-40.
31. Simkó J, Csilek A, Karászi J, Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection 2008 Jun;36(3):194-206.
32. Inghammar M, Nibell O, Pasternak B, Melbye M, Svanström H, Hviid A. Long-term risk of cardiovascular death with use of clarithromycin and roxithromycin: a nationwide cohort study. American Journal of Epidemiology 2018 Apr;187(4):777-85.
33. Lazareva NB, Shikh EV, Rebrova EV. Prospects of long-term treatment of macrolide antibiotics in bronchiectasis in children: questions and answers. Current Pediatrics 2018;17(2):166-9 (I Russian).
34. Choi Y, Lim HS, Chung D, Choi J, Yoon D. Risk evaluation of azithromycin-induced QT prolongation in real-world practice. BioMed Research International 2018 Oct 14;2018:1574806.
35. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. The New England Journal of Medicine 2004 Sep;351(11):1089-96.
36. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring 2007 Dec;29(6):687-710.
37. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clinical Pharmacokinetics 2005;44(9):915-34.
38. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clinical Pharmacokinetics 1993 Sep;25(3):189-204.
39. Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British Journal of Clinical Pharmacology 2000 Oct;50(4):285-95.
40. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrobial Agents and Chemotherapy 1991 Jun;35(6):1186-90.
41. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clinical Pharmacokinetics 1992 Aug;23(2):106-31.
42. Brar NK, Niederman MS. Management of community-acquired pneumonia: a review and update. Therapeutic Advances in Respiratory Disease 2011;5(1):61-78.
43. Kaysin A, Viera AJ. Community-acquired pneumonia in adults: diagnosis and management. American Family Physician 2016 Nov;94(9):698-706.
44. Russian Respiratory Society; Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC). Community-acquired pneumonia. Clinical guidelines. ICD-10: J13-J18. Moscow, 2018. 88 p. (In Russian).
45. Infectious morbidity in the Russian Federation in January-April 2018. Available from: http://rospotrebnadzor.ru/activities/statisticalmaterials/statictic_details.php?ELEMENT_ID=10158 Accessed 2019 Aug 13 (In Russian).
46. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007 Mar;44(Suppl 2):S27-S72.
47. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016 Oct;388(10053):1459-544.
48. Niederman MS, Luna CM. Community-acquired pneumonia guidelines: a global perspective. Seminars in Respiratory and Critical Care Medicine 2012 Jun;33(3):298-310.
49. Kozlov RS, Sivaya OV, Krechikova OI, Ivanchik NV, Shchetinin EV; PEHASus study group. Antimicrobial resistance of Streptococcus pneumoniae in Russia in 1999-2009: results of a multicenter prospective study PEHASus. Clinical Microbiology and Antimicrobial Chemotherapy 2010;12(4):329-41 (In Russian).
50. Torumkuney D, Mayanskiy N, Edelstein M, Sidorenko S, Kozhevin R, Morrissey I. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Russia. The Journal of Antimicrobial Chemotherapy 2018 Apr;73(Suppl 5):v14-v21.
51. Chuchalin AG, Sinopalnikov AI, Kozlov RS, Tyurin IE, Rachina SA. Community-acquired pneumonia in adults. Practical guidelines for diagnosis, treatment and prevention. Clinical Microbiology and Antimicrobial Chemotherapy 2010;12(3):186-225 (In Russian).
52. Cheng AC, Jenney AWJ. Macrolide resistance in pneumococci – is it relevant? Pneumonia (Nathan, Queensland) 2016 Jul;8:10.
53. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Critical Care Medicine 2014 Feb;42(2):420-32.
54. Elborn JS, Bell SC, Madge SL, Burgel PR, Castellani C, Conway S, De Rijcke K, Dembski B, Drevinek P, Heijerman HG, Innes JA, Lindblad A, Marshall B, Olesen HV, Reimann AL, Solé A, Viviani L, Wagner TO, Welte T, Blasi F. Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. The European Respiratory Journal 2016 Feb;47(2):420-8.
55. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. The Cochrane Database of Systematic Reviews 2012 Nov;(11):CD002203.
56. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M, Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, Murris-Espin M, Masefield S, Gerada E, Shteinberg M, Ringshausen F, Haworth C, Boersma W, Rademacher J, Hill AT, Aksamit T, O’Donnell A, Morgan L, Milenkovic B, Tramma L, Neves J, Menendez R, Paggiaro P, Botnaru V, Skrgat S, Wilson R, Goeminne P, De Soyza A, Welte T, Torres A, Elborn JS, Blasi F. The EMBARC European Bronchiectasis Registry: protocol for an international observational study. ERJ Open Research 2016 Jan;2(1). pii: 00081-2015. eCollection 2016 Jan.
57. McDonnell MJ, Aliberti S, Goeminne PC, Dimakou R, Zucchetti SC, Davidson J, Ward S, Laffey JG, Finch S, Pesci A, Dupont LJ, Fardon TC, Scrbic D, Obradovic D, Cowman S, Loebinger JM, Rutherford RM, De Souza A, Chalmers JD. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax 2016;71(12):1110-8.
58. Aliberti S, Lonni S, Dore S, McDonnell MJ, Goeminne PC, Dimakou K, Fardon TC, Rutherford R, Pesci A, Restrepo MI, Sotgiu G, Chalmers JD. Clinical phenotypes in adult patients with bronchiectasis. The European Respiratory Journal 2016 Apr;47(4):1113-22.
59. Kelly C, Chalmers JD, Crossingham I, Relph N, Felix LM, Evans DJ, Milan SJ, Spencer S. Macrolide antibiotics for bronchiectasis. The Cochrane Database of Systematic Reviews 2018;(3):CD012406.
60. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD Executive Summary. The European Respiratory Journal 2017 Mar;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar.
61. Cui Y, Luo L, Li C, Chen P, Chen Y. Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. International Journal of Chronic Obstructive Pulmonary Disease 2018 Nov;13:3813-29.
62. Gifford AМ, Chalmers JD. The role of neutrophils in cystic fibrosis. Current Opinion in Hematology 2014 Jan;21(1):16-22.
63. Barr HL, Halliday N, Cámara M, Barrett DA, Williams P, Forrester DL, Simms R, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Fogarty AW. Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis. The European Respiratory Journal 2015 Oct;46(4):1046-54.
64. Schögler A, Kopf BS, Edwards MR, Johnston SL, Casaulta C, Kieninger E, Jung A, Moeller A, Geiser T, Regamey N, Alves MP. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. The European Respiratory Journal 2015 Feb;45(2):428-39.
65. Tsai WC, Hershenson MB, Zhou Y, Sajjan U. Azithromycin increases survival and reduces lung inflammation in cystic fibrosis mice. Inflammation Research 2009 Aug;58(8):491-501.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]